Brief: Cocrystal Pharma Initiates Enrollment In Phase 1 Influenza A Study With Novel, Broad-Spectrum, Orally Administrated Antiviral Cc-42344
10/03/2022 14:07
March 10 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA INITIATES ENROLLMENT IN PHASE 1 INFLUENZA
A
STUDY WITH NOVEL, BROAD-SPECTRUM, ORALLY ADMINISTRATED ANTIVIRAL
CC-42344
Source text for Eikon: ID:nGNX7zJXyJ
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway